Logo image of LMAT

LEMAITRE VASCULAR INC (LMAT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LMAT - US5255582018 - Common Stock

88.27 USD
+1.77 (+2.05%)
Last: 1/16/2026, 8:00:00 PM
88.27 USD
0 (0%)
After Hours: 1/16/2026, 8:00:00 PM
Fundamental Rating

7

Taking everything into account, LMAT scores 7 out of 10 in our fundamental rating. LMAT was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making LMAT a very profitable company, without any liquidiy or solvency issues. LMAT is not valued too expensively and it also shows a decent growth rate. This makes LMAT very considerable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year LMAT was profitable.
  • In the past year LMAT had a positive cash flow from operations.
  • Each year in the past 5 years LMAT has been profitable.
  • Each year in the past 5 years LMAT had a positive operating cash flow.
LMAT Yearly Net Income VS EBIT VS OCF VS FCFLMAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1.2 Ratios

  • LMAT has a better Return On Assets (8.92%) than 91.40% of its industry peers.
  • With an excellent Return On Equity value of 14.08%, LMAT belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
  • LMAT's Return On Invested Capital of 8.43% is amongst the best of the industry. LMAT outperforms 87.10% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for LMAT is in line with the industry average of 8.84%.
  • The last Return On Invested Capital (8.43%) for LMAT is above the 3 year average (8.26%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.92%
ROE 14.08%
ROIC 8.43%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
LMAT Yearly ROA, ROE, ROICLMAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • LMAT has a better Profit Margin (22.14%) than 94.09% of its industry peers.
  • LMAT's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 25.71%, LMAT belongs to the best of the industry, outperforming 95.16% of the companies in the same industry.
  • In the last couple of years the Operating Margin of LMAT has grown nicely.
  • LMAT has a Gross Margin of 70.97%. This is in the better half of the industry: LMAT outperforms 79.57% of its industry peers.
  • LMAT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.71%
PM (TTM) 22.14%
GM 70.97%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
LMAT Yearly Profit, Operating, Gross MarginsLMAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

7

2. Health

2.1 Basic Checks

  • LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, LMAT has more shares outstanding
  • LMAT has more shares outstanding than it did 5 years ago.
  • LMAT has a worse debt/assets ratio than last year.
LMAT Yearly Shares OutstandingLMAT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LMAT Yearly Total Debt VS Total AssetsLMAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 7.47 indicates that LMAT is not in any danger for bankruptcy at the moment.
  • LMAT has a Altman-Z score of 7.47. This is amongst the best in the industry. LMAT outperforms 86.02% of its industry peers.
  • LMAT has a debt to FCF ratio of 2.54. This is a good value and a sign of high solvency as LMAT would need 2.54 years to pay back of all of its debts.
  • LMAT's Debt to FCF ratio of 2.54 is amongst the best of the industry. LMAT outperforms 84.41% of its industry peers.
  • LMAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • LMAT's Debt to Equity ratio of 0.44 is in line compared to the rest of the industry. LMAT outperforms 45.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 2.54
Altman-Z 7.47
ROIC/WACC0.85
WACC9.92%
LMAT Yearly LT Debt VS Equity VS FCFLMAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.3 Liquidity

  • LMAT has a Current Ratio of 13.58. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LMAT (13.58) is better than 97.85% of its industry peers.
  • A Quick Ratio of 11.45 indicates that LMAT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 11.45, LMAT belongs to the top of the industry, outperforming 95.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.58
Quick Ratio 11.45
LMAT Yearly Current Assets VS Current LiabilitesLMAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 19.67% over the past year.
  • LMAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.13% yearly.
  • Looking at the last year, LMAT shows a quite strong growth in Revenue. The Revenue has grown by 13.07% in the last year.
  • The Revenue has been growing by 13.41% on average over the past years. This is quite good.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.10% on average over the next years. This is quite good.
  • LMAT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.65% yearly.
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LMAT Yearly Revenue VS EstimatesLMAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
LMAT Yearly EPS VS EstimatesLMAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

5

4. Valuation

4.1 Price/Earnings Ratio

  • LMAT is valuated quite expensively with a Price/Earnings ratio of 40.31.
  • 70.43% of the companies in the same industry are more expensive than LMAT, based on the Price/Earnings ratio.
  • LMAT is valuated rather expensively when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 33.45, LMAT can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 72.04% of the companies listed in the same industry.
  • LMAT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 40.31
Fwd PE 33.45
LMAT Price Earnings VS Forward Price EarningsLMAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LMAT is valued a bit cheaper than 75.81% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, LMAT is valued cheaper than 81.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 30.24
EV/EBITDA 20.92
LMAT Per share dataLMAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of LMAT may justify a higher PE ratio.
  • A more expensive valuation may be justified as LMAT's earnings are expected to grow with 14.06% in the coming years.
PEG (NY)1.47
PEG (5Y)2.35
EPS Next 2Y16.63%
EPS Next 3Y14.06%

6

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.92%, LMAT is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.19, LMAT pays a better dividend. On top of this LMAT pays more dividend than 92.47% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, LMAT's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.92%

5.2 History

  • The dividend of LMAT is nicely growing with an annual growth rate of 13.60%!
  • LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
  • LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
LMAT Yearly Dividends per shareLMAT Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • LMAT pays out 32.20% of its income as dividend. This is a sustainable payout ratio.
  • LMAT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
LMAT Yearly Income VS Free CF VS DividendLMAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
LMAT Dividend Payout.LMAT Dividend Payout, showing the Payout Ratio.LMAT Dividend Payout.PayoutRetained Earnings

LEMAITRE VASCULAR INC

NASDAQ:LMAT (1/16/2026, 8:00:00 PM)

After market: 88.27 0 (0%)

88.27

+1.77 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners95.2%
Inst Owner Change4.07%
Ins Owners7.98%
Ins Owner Change-4.55%
Market Cap2.00B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.82
Price Target105.74 (19.79%)
Short Float %5.41%
Short Ratio6.52
Dividend
Industry RankSector Rank
Dividend Yield 0.92%
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.64%
PT rev (3m)-1.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.33%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)6.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.94%
Valuation
Industry RankSector Rank
PE 40.31
Fwd PE 33.45
P/S 8.32
P/FCF 30.24
P/OCF 27.33
P/B 5.29
P/tB 7.12
EV/EBITDA 20.92
EPS(TTM)2.19
EY2.48%
EPS(NY)2.64
Fwd EY2.99%
FCF(TTM)2.92
FCFY3.31%
OCF(TTM)3.23
OCFY3.66%
SpS10.62
BVpS16.7
TBVpS12.4
PEG (NY)1.47
PEG (5Y)2.35
Graham Number28.69
Profitability
Industry RankSector Rank
ROA 8.92%
ROE 14.08%
ROCE 10.97%
ROIC 8.43%
ROICexc 21.47%
ROICexgc 38.36%
OM 25.71%
PM (TTM) 22.14%
GM 70.97%
FCFM 27.5%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 2.54
Debt/EBITDA 2.33
Cap/Depr 68.51%
Cap/Sales 2.93%
Interest Coverage 250
Cash Conversion 101.46%
Profit Quality 124.17%
Current Ratio 13.58
Quick Ratio 11.45
Altman-Z 7.47
F-Score5
WACC9.92%
ROIC/WACC0.85
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year45.26%
EBIT Next 3Y22.27%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%

LEMAITRE VASCULAR INC / LMAT FAQ

What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to LMAT.


What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a valuation rating of 5 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.


How profitable is LEMAITRE VASCULAR INC (LMAT) stock?

LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.


What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 40.31 and the Price/Book (PB) ratio is 5.29.


How financially healthy is LEMAITRE VASCULAR INC?

The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 7 / 10.